19:30 , Jun 15, 2018 |  BC Week In Review  |  Company News

ChemoCentryx, Vifor Fresenius expand CCX140, avocapan deal to include China

ChemoCentryx Inc. (NASDAQ:CCXI) granted Vifor Fresenius Medical Care Renal Pharma Ltd. exclusive rights to commercialize avacopan (CCX168) and CCX140 in China under the second expansion of a 2016 deal. Vifor Fresenius gained exclusive commercialization rights...
16:40 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

ChemoCentryx reports OS data for CCR2 antagonist in pancreatic cancer

ChemoCentryx Inc. (NASDAQ:CCXI) said CCX872 plus FOLFIRINOX chemotherapy led to an 18-month overall survival rate of 29% in a Phase Ib trial to treat advanced non-resectable pancreatic cancer. The company will present the data at...
22:32 , Jan 23, 2018 |  BC Extra  |  Clinical News

ChemoCentryx reports OS data for CCR2 antagonist in pancreatic cancer

ChemoCentryx Inc. (NASDAQ:CCXI) said CCX872 plus FOLFIRINOX chemotherapy led to an 18-month overall survival rate of 29% in a Phase Ib trial to treat advanced non-resectable pancreatic cancer. The company will present the data on...
23:21 , Jan 9, 2018 |  BC Extra  |  Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
00:44 , Jan 5, 2018 |  BC Extra  |  Company News

ChemoCentryx gains after EMA validates avacopan MAA

ChemoCentryx Inc. (NASDAQ:CCXI) jumped $2.44 (39%) to $8.63 Thursday after it said EMA validated an MAA for avacopan (CCX168), triggering a $50 million milestone payment from Vifor Fresenius Medical Care Renal Pharma Ltd. ChemoCentryx also...
20:58 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; lung cancer Mouse studies suggest inhibiting CCR2 in combination with radiotherapy could help treat colon and lung cancers. In mouse models of colon and lung cancers, systemic knockout of CCR2 plus radiation decreased...
19:22 , Nov 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinopathy of prematurity Patient sample and mouse studies suggest inhibiting mast cell degranulation, TPSB2 or MCP-1-CCR2 signaling could help treat retinopathy of prematurity (ROP). In plasma samples from preterm neonatal infants who developed ROP, levels...
19:21 , Nov 15, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers; other

TECHNOLOGY: Serum markers; computational models A computational model based on mucosal-associated invariant T cell expression of CCR6, CD56, CD25 and PD-1 in blood could help diagnose Type I diabetes. In peripheral blood samples from adult patients...
22:23 , Aug 11, 2017 |  BioCentury  |  Regulation

Foundation for inclusion

Hosting a patient-focused drug development workshop was the National Kidney Foundation Inc.’s first step in assuming the role of facilitator to collect patient perspectives that will shape R&D for kidney disease. On Aug. 4, the advocacy...
01:06 , Aug 4, 2017 |  BC Extra  |  Politics & Policy

National Kidney Foundation holding patient-focused meeting with FDA

On Friday, the National Kidney Foundation (NKF) will lead a patient-focused drug development (PFDD) meeting on complement 3 glomerulopathy (C3G), a rare kidney disease, in the hopes of advancing development of innovative treatments for the...